

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	2869	(insulin-like adj growth adj factor-1) or IGF-1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 09:51		0	
2	BRS	L2	459	solubilizing adj compound	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 09:52		0	
3	BRS	L3	53675	arginine or (guanidine adj hydrochloride) or N-acetyl-arginine or guanidinium	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 09:53		0	
4	BRS	L4	1499	3 same solubiliz\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 09:53		0	
5	BRS	L5	14	1 same 4	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:30		0	
6	BRS	L6	2	5410026.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:11		0	
7	BRS	L7	684	"12" adj mg/ml	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:37		0	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
8	BRS	L8	1963	"200" adj mg/ml	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:38		0	
9	BRS	L9	1	5 same (7 or 8)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:38		0	
10	BRS	L10	14	shirley adj bret.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:38		0	
11	BRS	L11	1	bajwa adj kamaljit.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:39		0	
12	BRS	L12	2	(10 or 11) and 5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/12 10:39		0	

FILE 'MEDLINE' ENTERED AT 10:43:56 12 AUG 2003

FILE 'CAPLUS' ENTERED AT 10:43:56 ON 12 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:43:56 ON 12 AUG 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 10:43:56 ON 12 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 10:43:56 ON 12 AUG 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 10:43:56 ON 12 AUG 2003

=> s (insulin-like growth factor-1) or IGF-1
L1 29701 (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-1

=> s arginine or guanidine or guanidium
L2 406219 ARGININE OR GUANIDINE OR GUANIDIUM

=> s l2 (p) solubiliz?
L3 2954 L2 (P) SOLUBILIZ?

=> s l1 (p) l3
L4 5 L1 (P) L3

=> duplicate remove l4
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L4
L5 2 DUPLICATE REMOVE L4 (3 DUPLICATES REMOVED)

=> d l5 1-2 ibib abs

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:325815 CAPLUS
DOCUMENT NUMBER: 130:343031
TITLE: Compositions providing for increased IGF-I solubility
INVENTOR(S): Shirley, Bret A.; Bajwa, Kamaljit
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924063	A1	19990520	WO 1998-US23673	19981106
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9915193	A1	19990531	AU 1999-15193	19981106
EP 1028748	A1	20000823	EP 1998-959383	19981106
EP 1028748	B1	20030502		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001522814	T2	20011120	JP 2000-520151	19981106
AT 238807	E	20030515	AT 1998-959383	19981106
PRIORITY APPLN. INFO.:			US 1997-64891P	P 19971107
			WO 1998-US23673	W 19981106

AB IGF-I compns. include a solubilizing compd. comprising a guanidinium group that provides for IGF-I compns. in which IGF-I is highly sol. at pHs of about 5.5 or greater and at refrigerated temps. IGF-I was formulated with arginine for injection.

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THIS FORMAT

L5 ANSWER 2 OF 2

MEDLINE on STN

DUPLICATE 1

ACCESSION NUMBER:

92316967 MEDLINE

DOCUMENT NUMBER:

92316967 PubMed ID: 1618780

TITLE:

Enhanced insulin-induced mitogenesis and mitogen-activated protein kinase activities in mutant insulin receptors with substitution of two COOH-terminal tyrosine autophosphorylation sites by phenylalanine.

AUTHOR:

Ando A; Momomura K; Tobe K; Yamamoto-Honda R; Sakura H; Tamori Y; Kaburagi Y; Koshio O; Akanuma Y; Yazaki Y; +

CORPORATE SOURCE:

Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

SOURCE:

JOURNAL OF BIOLOGICAL CHEMISTRY, (1992 Jun 25) 267 (18) 12788-96.

Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY:

United States

DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199208

ENTRY DATE:

Entered STN: 19920815

Last Updated on STN: 20000303

Entered Medline: 19920806

AB

We have studied the function of a mutant human insulin receptor in which two COOH-terminal autophosphorylation sites (Tyr-1316 and -1322) were replaced by phenylalanine (F/Y COOH-terminal 2 tyrosines (CT2)). In addition, we have also constructed a mutant receptor in which Lys-1018 in the ATP-binding site was changed to ***arginine*** (R/K 1018). Both the wild type insulin receptor (HIR) and the mutant receptors were expressed in Chinese hamster ovary (CHO) cells by stable transfection. Autophosphorylation of ***solubilized*** and partially purified F/Y CT2 was decreased by approximately 30% compared with the HIR. Tyrosine kinase activities of F/Y CT2 and HIR toward exogenous substrates were almost equal. When CHO cells transfected with F/Y CT2 (CHO-F/Y CT2) were stimulated with insulin, autophosphorylation of the beta-subunit of the insulin receptor and the phosphorylation of an endogenous substrate (pp185) in the intact cell were normal compared with cells expressing HIR (CHO-HIR). CHO-F/Y CT2 exhibited the same insulin sensitivity as CHO-HIR with respect to 2-deoxyglucose uptake. However, the dose-response curve of insulin-stimulated thymidine incorporation in CHO-F/Y CT2 was shifted to the left (approximately 5-7-fold) compared with that in CHO-HIR. There was no significant difference in ***insulin*** - ***like***

growth ***factor*** ***1*** -stimulated thymidine incorporation between CHO-F/Y CT2 and CHO-HIR. Furthermore, the dose-response curve of insulin-stimulated kinase activity toward myelin basic protein in CHO-F/Y CT2 was also shifted to the left (approximately 5-fold) compared with that in CHO-HIR. Kinase assays in myelin basic protein-containing gels revealed that both species of MAP kinases (M(r) 44,000, 42,000) were more sensitive to activation by insulin in CHO-F/Y CT2 than in CHO-HIR. This observation was confirmed in immune complex kinase assays toward microtubule-associated protein 2 (MAP2) using specific antibodies against mitogen-activated protein (MAP) kinase. R/K 1018 mutant insulin receptors showed an absence of insulin-stimulated kinase activity and CHO cells transfected with R/K 1018 (CHO-R/K 1018) failed to enhance 2-deoxyglucose uptake or thymidine incorporation in response to insulin. In addition, R/K 1018 kinase-defective insulin receptors were unable to mediate insulin-stimulated MAP kinase activation. These data suggest that: 1) tyrosine kinase activity of the insulin receptor is required for activation of insulin-stimulated MAP kinases and 2) phosphorylation of COOH-terminal tyrosine residues may play an inhibitory role in mitogenic signaling through regulation of MAP kinases.

=> d his

(FILE 'HOME' ENTERED AT 10:43:34 ON 12 AUG 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 10:43:56 ON 12 AUG 2003

L1

29701 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-1

L2

406219 S ARGININE OR GUANIDINE OR GUANIDIUM

L3

2954 S L2 (P) SOLUBILIZ?

L4

5 S L1 (P) L3

L5

2 DUPLICATE REMOVE L4 (3 DUPLICATES REMOVED)

=> s (12 mg/ml) or (200 mg/ml)
'ML' IS NOT A VALID FIELD CODE
'ML' IS NOT A VALID FIELD CODE
'ML' IS NOT A VALID FIELD CODE
'ML' IS NOT A VALID FIELD CODE
L6 0 (12 MG/ML) OR (200 MG/ML)

=> s shirley bret/au
L7 6 SHIRLEY BRET/AU

=> s bajwa kamaljit/au
L8 2 BAJWA KAMALJIT/AU

=> s (17 or 18) and 11
L9 3 (L7 OR L8) AND L1

=> duplicate remove 19
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L9
L10 3 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)

=> d 110 1-3 ibib abs

L10 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:313118 BIOSIS
DOCUMENT NUMBER: PREV200300313118
TITLE: Method for producing sustained-release formulations.
AUTHOR(S): ***Shirley, Bret*** ; Hora, Maninder; O'Hagan, Derek;
Singh, Manmohan
ASSIGNEE: Chiron Corporation
PATENT INFORMATION: US 6573238 June 03, 2003
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (June 3 2003) Vol. 1271, No. 1, pp. No
Pagination. <http://www.uspto.gov/web/menu/patdata.html>.
e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
AB Methods for preparing biodegradable microparticles are provided. Also
provided are microparticles prepared by the method which include
IGF - ***1*** entrapped therein. The microparticles allow for
controlled release of ***IGF*** - ***1*** and other polypeptides
over prolonged periods of time.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:325815 CAPLUS
DOCUMENT NUMBER: 130:343031
TITLE: Compositions providing for increased IGF-I solubility
INVENTOR(S): Shirley, Bret A.; ***Bajwa, Kamaljit***
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924063	A1	19990520	WO 1998-US23673	19981106
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9915193	A1	19990531	AU 1999-15193	19981106
EP 1028748	A1	20000823	EP 1998-959383	19981106
EP 1028748	B1	20030502		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001522814	T2	20011120	JP 2000-520151	19981106
AT 238807	E	20030515	AT 1998-959383	19981106

PRIORITY APPLN. INFO.:

US 1997-64891P P 19971107

WO 1998-US23673 W 19981106

AB IGF-I compns. include a solubilizing compd. comprising a guanidinium group that provides for IGF-I compns. in which IGF-I is highly sol. at pHs of about 5.5 or greater and at refrigerated temps. IGF-I was formulated with arginine for injection.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:325813 CAPLUS

DOCUMENT NUMBER: 130:343029

TITLE: Method for producing ***IGF*** - ***1*** sustained-release formulations

INVENTOR(S): ***Shirley, Bret*** ; Hora, Maninder; O'Hagan, Derek; Singh, Manmohan

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924061	A1	19990520	WO 1998-US23627	19981106
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9913841	A1	19990531	AU 1999-13841	19981106
EP 1028746	A1	20000823	EP 1998-957624	19981106
EP 1028746	B1	20030226		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001522812	T2	20011120	JP 2000-520149	19981106
US 2002013273	A1	20020131	US 1998-187780	19981106
US 6573238	B2	20030603		
AT 233097	E	20030315	AT 1998-957624	19981106

PRIORITY APPLN. INFO.:

US 1997-64891P P 19971107

US 1998-96066P P 19980811

WO 1998-US23627 W 19981106

AB Methods for prepg. biodegradable poly(D,L-lactide-co-glycolide) microparticles are provided. Also provided are microparticles prepd. by the method which include ***IGF*** - ***1*** entrapped therein. The microparticles allow for controlled release of ***IGF*** - ***1*** and other polypeptides over prolonged periods of time.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:43:34 ON 12 AUG 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 10:43:56 ON 12 AUG 2003

L1 29701 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-1
L2 406219 S ARGININE OR GUANIDINE OR GUANIDINIUM
L3 2954 S L2 (P) SOLUBILIZ?
L4 5 S L1 (P) L3
L5 2 DUPLICATE REMOVE L4 (3 DUPLICATES REMOVED)
L6 0 S (12 MG/ML) OR (200 MG/ML)
L7 6 S SHIRLEY BRET/AU
L8 2 S BAJWA KAMALJIT/AU
L9 3 S (L7 OR L8) AND L1
L10 3 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

41.35

TOTAL

SESSION

41.56

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY
-1.95

TOTAL
SESSION
-1.95

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:50:32 ON 12 AUG 2003